ArticleClinical and molecular hepatology2022
Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis.
Article in Clinical and molecular hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Effect of adipose-related parameters on mortality in patients with liver cirrhosis: a meta-analysis.Annals of medicine · 2025Pooled it
- Correlation between sarcopenia and cirrhosis: a meta-analysis.Frontiers in nutrition · 2023Pooled it
- Role of Renal Biomarkers in Sarcopenia or Frailty in Patients With Liver Cirrhosis.Journal of Korean medical science · 2026Article
- Identification of PTPRR gene associated with cirrhosis and sarcopenia based on bioinformatics and machine learning.European journal of clinical nutrition · 2026Article
- Article
- Effect of Nutritional Status on Coagulation and Inflammation in Patients With Cirrhosis and Variceal Bleeding.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Proton Beam Therapy Provides Longer Survival and Preserves Muscle Mass in Hepatocellular Carcinoma Compared to TACE+RFA.Cancers · 2025Article
- Review
- Accelerated muscle mass estimation from CT images through transfer learning.BMC medical imaging · 2024Article
- Alcohol-associated liver disease increases the risk of muscle loss and mortality in patients with cirrhosis.Journal of gastroenterology · 2024Article
- Muscle mass dynamics is independently associated with long-term liver-related mortality in patients with cirrhosis.Heliyon · 2024Article
- Sarcopenia evaluated by EASL/AASLD computed tomography-based criteria predicts mortality in patients with cirrhosis: A systematic review and meta-analysis.JHEP reports : innovation in hepatology · 2024Article
- Appendicular Skeletal Muscle Mass to Visceral Fat Area Ratio Predicts Hepatic Morbidities.Gut and liver · 2024Article
- Pretransplant Functional Status Predicts Postoperative Morbidity and Mortality after Liver Transplantation in Patients with Cirrhosis.Gut and liver · 2023Article
- How to deliver palliative care for patients with management in decompensated cirrhosis.Hepatobiliary surgery and nutrition · 2023Article
- Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota.World journal of gastroenterology · 2023Review
- Interaction between sarcopenia and nonalcoholic fatty liver disease.Clinical and molecular hepatology · 2023Review
- Correspondence on Letter regarding "Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis".Clinical and molecular hepatology · 2023Article
- Letter regarding "Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis".Clinical and molecular hepatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND/
aimsSarcopenia negatively affects the prognosis of cirrhotic patients, but clinical implications of changes in muscle mass remain unclear. We aimed to elucidate its role in the prognosis of outpatients with cirrhosis.
methodsPatients with cirrhosis who underwent annual abdominal computed tomography (CT) for hepatocellular carcinoma surveillance were included in the prospective cohort. The L3 skeletal muscle index (SMI) was adopted as a proxy for the amount of skeletal muscle, and the rate of SMI change between inclusion and after 1 year (ΔSMI/yr%) was calculated.
resultsIn total, 595 patients underwent a second CT after 1 year. Among them, 109 and 64 patients had sarcopenia and Child-Pugh class B/C decompensation at inclusion, which changed to 103 and 45 at the 1-year follow-up, respectively. During a median follow-up of 30.1 months after 1 year, 86 patients had at least one cirrhosis complication, and 18 died or received liver transplantation. In the development of cirrhosis complications, ΔSMI/yr% was independently associated, even after adjusting for the Child-Pugh and model for end stage liver disease (MELD)-Na scores. In addition, ΔSMI/yr% showed a good predictive performance for the development of cirrhosis complications within 6 months after 1-year follow-up in all subgroups, with a cut-off of -2.62 (sensitivity, 83.9%; specificity, 74.5%) in the overall population. SMI at 1-year and Child-Pugh score were independent factors associated with survival. In addition, changes in sarcopenia status significantly stratified survival.
conclusionΔSMI/yr% was a good predictor of the development of cirrhosis complications in outpatients with cirrhosis, independent of Child-Pugh and MELD scores.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.